GeminIQ Website Logo

Viewing TTRX free

Subscribe for full history, 90+ metrics, screener, watchlist...

Turn Therapeutics Inc.

TTRX

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial
Subscriber-only column
Assets
Assets Current
Cash Equivalents At Carrying Value
101153
Prepaid Expense And Other Assets Current
0000
Assets Current
101153
Operating Lease Right Of Use Asset
0000
Intangible Assets Net Excluding Goodwill
1111
Deferred Costs
666-
Security Deposit
0000
Assets
1719124
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Other Accrued Liabilities Cur…
3232
Derivative Liabilities Current
633-
Operating Lease Liability Current
0000
Liabilities Current
9562
Operating Lease Liability Noncurrent
0000
Long Term Debt Noncurrent
66--
Contract With Customer Liability Noncurrent
1111
Liabilities
161374
Stockholders Equity
Common Stock Value
0000
Additional Paid In Capital Common Stock
30292823
Stockholders Equity Note Subscriptions Receivable
---1-0
Retained Earnings Accumulated Deficit
-29-23-22-23
Stockholders Equity
1651
Liabilities And Stockholders Equity
1719124
Common Stock Par Or Stated Value Per Share
0000
Common Stock Shares Authorized
500500500500
Common Stock Shares Issued
30302928

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
202636.08%83.51%112.63%---------
2025------5.38%14.67%0.73%10.78%60.31%83.44%

Earnings Market Reaction data beyond 3 years is for subscribers only.

Unlock the full earnings market reaction history

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Metric history beyond 3 years is for subscribers only.

Unlock 17+ years of history across 90+ calculated metrics

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
1.19
2.23
0.87
1.43
Quick Ratio
1.17
2.19
0.85
1.35
Working Capital
1.66M
6.32M
-806.98K
985.49K
Leverage & Debt
Debt to Equity
23.69
2.05
1.60
7.53
Debt Ratio
0.96
0.67
0.61
0.88
Efficiency & Turnover
Asset Turnover TTM
0.00
-
-
-
Per Share Metrics
Diluted EPS TTM
-0.34
-
-
-
Free Cash Flow Per Share TTM
-0.12
-
-
-
Dividend Per Share TTM
0.00
-
-
-
Valuation Metrics
P/E TTM
-21.71
-
-
-
P/B TTM
316.58
15.42
23.30
-
Market Cap
217.45M
94.32M
109.20M
-
Enterprise Value
213.23M
89.04M
104.13M
-
Calculated Values
Free Cash Flow TTM
-3.66M
-
-
-
Net Debt
-4.23M
-5.28M
-5.08M
-3.11M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2025-12-12Purchase
Owner: Chaudhary, Zuraiz
Title: See Remarks
Shares: 2,500
Price/Share: $3.50
Value: $8,750.00
Shares Owned: 12,500
Relationship: Officer
Ownership: Direct
2025-11-24Purchase
Owner: Golden, Arthur F
Title: -
Shares: 9,868
Price/Share: $3.44
Value: $33,945.92
Shares Owned: 60,602
Relationship: Director
Ownership: Direct
2025-11-21Purchase
Owner: Chaudhary, Zuraiz
Title: See Remarks
Shares: 1,000
Price/Share: $3.29
Value: $3,290.00
Shares Owned: 10,000
Relationship: Officer
Ownership: Direct
2025-11-21Purchase
Owner: Golden, Arthur F
Title: -
Shares: 20,532
Price/Share: $2.87
Value: $58,926.84
Shares Owned: 50,734
Relationship: Director
Ownership: Direct
2025-11-17Purchase
Owner: Chaudhary, Zuraiz
Title: See Remarks
Shares: 2,500
Price/Share: $3.62
Value: $9,050.00
Shares Owned: 7,550
Relationship: Officer
Ownership: Direct

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2026-03-31
1.57%
Inst. Shares: 462,310
Shares Outstanding: 29,476,002
2025-12-31
1.68%
Inst. Shares: 466,461
Shares Outstanding: 27,716,045

Turn Therapeutics Inc. (TTRX) — SEC Financial Statements & Analysis

Turn Therapeutics Inc. (TTRX) is a pharmaceutical preparations company, incorporated in DE. Turn Therapeutics Inc. trades on Nasdaq as: TTRX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Turn Therapeutics Inc. reported a Debt-to-Equity ratio of 23.69x, a Price-to-Book (P/B) ratio of 316.58x (TTM), at a market cap of $217.45M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity
23.69x
P/B TTM
316.58x
Market Cap
$217.45M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Turn Therapeutics Inc. in?

Turn Therapeutics Inc. (TTRX) operates in the Pharmaceutical Preparations industry.

What is TTRX's market cap?

Turn Therapeutics Inc. (TTRX) has a market capitalization of $217.45M as of 2026-06-30.

What exchange does TTRX trade on?

Turn Therapeutics Inc. (TTRX) trades on the Nasdaq.

Where is Turn Therapeutics Inc. incorporated?

Turn Therapeutics Inc. is incorporated in DE.

Wall Street's data.
Main Street's price.